Eos SENOLYTIX has begun publishing daily cage-camera footage and locomotor scoring for a 167-week-old mouse treated weekly with its mitochondrial-targeted geropeptide PTC-2105, alongside the underlying preclinical survival data including non-significant results. The treated animal has outlived its strain's typical ceiling of roughly 155 weeks and shows greater nocturnal activity than untreated mice 66 weeks younger. A parallel study reported that mice given a single on-off cycle of semaglutide alone experienced steep late-life decline, with the last dying before the last saline control.
Key Points
- Treated mouse reached 167 weeks; strain rarely exceeds 155 weeks
- Nocturnal activity exceeded untreated mice 66 weeks younger
- Semaglutide-only cycle preceded steep terminal decline versus saline controls
Longevity Analysis
Lifespan extension matters only when movement, energy output and night-time activity extend with it, and continuous home-cage monitoring captures that distinction in a way endpoint survival curves cannot. The semaglutide observation raises a separate question about whether a metabolic intervention that performs well on weight and glycemia may carry a late-life cost that trial designs have not been built to detect — a reminder that removing an apparent problem can introduce one further downstream. Publishing daily footage and non-significant results in advance of an outcome that will eventually read DECEASED sets an unusually verifiable standard for how preclinical geroscience data are shared.
Original published by Longevity.Technology, by Eleanor Garth.